Stocks TelegraphStocks Telegraph
Stock Ideas

BIO Company Profile and Key Details

NYSE : BIO

Bio-Rad Laboratories

$283.86
-8.64-2.95%
At Close 4:00 PM
52.07
B-ESG ScoreESG Rating

Price Chart

Stock Price Today

Bio-Rad Laboratories, Inc. (BIO) stock declined over -2.95%, trading at $283.86 on NYSE, down from the previous close of $292.50. The stock opened at $289.28, fluctuating between $281.79 and $290.50 in the recent session.

Stock Snapshot

292.5
Prev. Close
7.67B
Market Cap
281.79
Day Low
30.62
P/E Ratio
9.27
EPS (TTM)
7.58
Cash Flow per Share
289.28
Open
27.04M
Number of Shares
290.5
Day High
84.05%
Free Float in %
303.6
Book Value
241.23K
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Jul 08, 2026289.19290.50281.79283.86241.22K
Jul 07, 2026298.37298.65290.00292.50293.98K
Jul 06, 2026298.82298.82290.93295.15270.78K
Jul 02, 2026298.00302.55295.84296.86329.92K
Jul 01, 2026293.11299.54293.06297.09204.2K
Jun 30, 2026296.79299.32287.94293.61235.28K
Jun 29, 2026300.00301.27294.07295.30308.97K
Jun 26, 2026296.80305.00293.46300.79437.47K
Jun 25, 2026284.00301.76280.78298.29591K
Jun 24, 2026273.35284.02270.00280.05316.05K
Jun 23, 2026281.62283.76270.28270.32639.14K
Jun 22, 2026281.15281.93276.51281.11236.8K
Jun 18, 2026284.61285.75280.48282.44398.18K
Jun 17, 2026288.78293.11282.69284.67203.88K
Jun 16, 2026290.65294.43288.94289.95266.64K
Jun 15, 2026288.77292.51285.03289.28226.46K
Jun 12, 2026293.57293.83284.57285.94178.97K
Jun 11, 2026292.41297.13287.73292.44365.44K
Jun 10, 2026296.08298.58290.21291.01370.81K
Jun 09, 2026294.30297.92290.35297.17429.12K

Contact Details

Hercules, CA 94547

United States

https://www.bio-rad.com510 724 7000

About Company

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

Company Information

Employees7700
Beta1.08
Sales or Revenue$2.67B
5Y Sales Change%0.191%
Fiscal Year EndsDecember
SectorHealthcare
IndustryMedical - Devices

Company Overview

Bio-Rad Laboratories, Inc. (NYSE:BIO) closed at $283.86 USD, losing -$8.64 (-2.95%) from the previous close of $292.50. The stock is currently mid-range between its 52-week high and low $236.73 and $343.12. With a market capitalization of about $7.67 billion, Bio-Rad Laboratories, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.08). Key stats such as the average daily volume over the past year has been around 380.80 thousand shares, volume is running light vs its 52-week average. Headquartered in Hercules, CA, Bio-Rad Laboratories, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Norman D. Schwartz, the company employs approximately 7,700 people and listed since February 27, 1980. Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -3.26%, SMA50 -8.05%, SMA200 -2.85%). The stock’s 14-day RSI is 41.06 (neutral), while the ATR of 10.02 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -19.78% below its high and over 30.18% above its low. Average 10-day trading volume of 269.19 thousand shares is below the 3-month average of 366.53 thousand, indicating normal recent market interest.

Valuation Metrics

Bio-Rad Laboratories, Inc. trades at a P/E ratio of 46.39, slightly above the S&P 500 average, with a price-to-sales ratio of 2.96 and a price-to-book ratio of 1.12 suggesting the stock is closer to book value. The P/FCF stands at 21.45, also above market averages.

Dividend & Fair Value

Bio-Rad Laboratories, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $166.83. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Bio-Rad Laboratories, Inc. generated EPS of $27.92 over the past year. Five-year average earnings growth is -26.08%. Wall Street analysts project EPS growth of 8.33% annually over the next five years. The latest quarter delivered EPS of -$19.55. The next quarter is forecast at $1.97. Next year's EPS is expected at $0.99. Analyst sentiment is neutral. Analyst rating data shows there are 2 Strong Buy ratings, 1 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $409.00 to $265.00. The high target offers 44.09% upside. The low target suggests -6.64% downside. The mean target is $328.43. This offers 15.7% upside. Bio-Rad Laboratories, Inc. earnings surprise history is a mixed track record. The quarter that ended April 30, 2026, missed forecasts by -1092.39%. The prior quarter beat by -2.33%. Over the last six quarters, Apple has recorded several small beats. These include 1.4% in February 13, 2025.

Frequently Asked Questions

What is the current Bio-Rad Laboratories, Inc. (BIO) stock price?
Bio-Rad Laboratories, Inc. (NYSE: BIO) stock price is $283.86 in the last trading session. During the trading session, BIO stock reached the peak price of $290.50 while $281.79 was the lowest point it dropped to. The percentage change in BIO stock occurred in the recent session was -2.95% while the dollar amount for the price change in BIO stock was - $8.64.
BIO's industry and sector of operation?
The NYSE listed BIO is part of Medical - Devices industry that operates in the broader Healthcare sector. Bio-Rad Laboratories, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of BIO?
Mr. Yong Chung
Vice President of Investor Relations
Dr. Andrew J. Last Ph.D.
Executive Vice President & Chief Operating Officer
Dr. Simon May
Executive Vice President & Pres of the Life Science Group
Mr. Norman D. Schwartz
Chairman, Chief Executive Officer & Pres
Mr. Michael Crowley
Executive Vice President of Global Commercial Operations
Mr. Ilan Daskal
Executive Vice President & Chief Financial Officer
Mr. Ajit Ramalingam
Senior Vice President & Chief Accounting Officer
Lee Boyd
Senior Vice President of Global Commercial Operations - Asia Pacific
Colleen Corey
Executive Vice President of Global HR
Mr. Timothy S. Ernst
Executive Vice President, Gen. Counsel & Sec.
Ms. Dara Grantham Wright
Executive Vice President & Pres of Clinical Diagnostics Group
Matthew Werner
Senior Vice President and Chief Compliance & Privacy Officer
How BIO did perform over past 52-week?
BIO's closing price is 19.91% higher than its 52-week low of $236.73 where as its distance from 52-week high of $343.12 is -17.27%.
How many employees does BIO have?
Number of BIO employees currently stands at 7,700.
Link for BIO official website?
Official Website of BIO is: https://www.bio-rad.com
How do I contact BIO?
BIO could be contacted at phone 510 724 7000 and can also be accessed through its website. BIO operates from 1000 Alfred Nobel Drive, Hercules, CA 94547, United States.
How many shares of BIO are traded daily?
BIO stock volume for the day was 241.23K shares. The average number of BIO shares traded daily for last 3 months was 380.8K.
What is the market cap of BIO currently?
The market value of BIO currently stands at $7.67B with its latest stock price at $283.86 and 27.04M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph